Auditory evoked potentials in young patients with Down syndrome. Event-related potentials (P3) and histaminergic system.
Subjects with Down syndrome exhibit various types of cognitive impairment. Besides abnormalities in a number of neurotransmitter systems (e.g. cholinergic), histaminergic deficits have recently been identified. Brainstem auditory evoked potentials (BAEPs) and auditory event-related potentials (ERPs), were recorded from 10 children (aged 11-20 years) with Down syndrome and from 10 age- and sex-matched healthy control subjects. In Down subjects, BAEPs revealed shortened latencies for peaks III and V with shortened interpeak latencies I-III and I-V. ERPs showed a delay of components N1, P2, N2 and P3. In addition, subjects with Down syndrome failed to show P3 amplitude reduction during repeated stimulation. To evaluate the cognitive effects of histaminergic dysfunction, ERPs were recorded from 12 healthy adults (aged 20-28 years) before and after antihistaminergic intervention (pheniramine) compared to placebo. Whereas components N1, P2, N2 remained unchanged after H1-receptor antagonism, P3 latency increased and P3 amplitude showed no habituation in response to repeated stimulation. The results suggest that the characteristic neurofunctional abnormalities present in children with Down syndrome must be the consequence of a combination of structural and neurochemical aberrations. The second finding was that antihistaminergic treatment affects information processing tested by ERPs similar to that seen with anticholinergic treatment.
Seidl
R
R
Department of Pediatrics, University Hospital Vienna, Austria.
Hauser
E
E
Bernert
G
G
Marx
M
M
Freilinger
M
M
Lubec
G
G
D000293:Adolescent; D000328:Adult; D002648:Child; D004314:Down Syndrome / Q000503:physiopathology*; D005072:Evoked Potentials, Auditory / Q000187:drug effects; D016057:Evoked Potentials, Auditory, Brain Stem / Q000187:drug effects; D005260:Female; D006632:Histamine / Q000502:physiology*; D006634:Histamine H1 Antagonists / Q000494:pharmacology; D006801:Humans; D008297:Male; D010632:Pheniramine / Q000494:pharmacology; D012016:Reference Values
D006634:Histamine H1 Antagonists; D010632:Pheniramine; D006632:Histamine